Table 3.
Comparison of DELIVER and other trials in heart failure with left ventricular ejection fraction >40%
| CHARM‐Preserved22 | PEP‐CHF23 | I‐PRESERVE24 | TOPCAT25 | PARAGON‐HF17 | EMPEROR‐Preserved26 | DELIVER | |
|---|---|---|---|---|---|---|---|
| Patients, n | 3023 | 850 | 4128 | 3445 | 4800 | 5988 | 6200 |
| Treatment arms | Candesartan vs. placebo | Perindopril vs. placebo | Irbesartan vs. placebo | Spironolactone vs. placebo | Sacubitril/valsartan vs. valsartan | Empagliflozin vs. placebo | Dapagliflozin vs. placebo |
| Key inclusion criteria | NYHA class II–IV, prior CV hospitalization | Clinical diagnosis of DHF with ≥signs/symptoms of HF, ≥2 of the following: LAE/LVH/impaired left ventricular filling/AF | NYHA class II–IV + any corroborating evidence (e.g. HF sign), LVH or LAE considered optional corroborating evidence, HFH required unless in NYHA class III–IV | ≥1 HF symptom + ≥1 HF sign, elevated NP or HFH | NYHA class II–IV, elevated NT‐proBNP (adjusted for AF and higher if no recent HF hospitalization), structural heart disease (LAE or LVH) | NYHA class II–IV, elevated NT‐proBNP | NYHA class II–IV, elevated NT‐proBNP (adjusted for AF), structural heart disease (LAE or LVH) |
| LVEF cutpoint | >40% | >40% | ≥45% | ≥45% | ≥45% | >40% | >40% |
| Endpoint | First of either CV death or HFH | First of either all‐cause death of HFH | First of either all‐cause death or hospitalization for a CV cause | First of either CV death, HFH, or RSD | CV death and total HFH (first and recurrent) | CV death or HFH | CV death or HFH either in the full population or in patients with LVEF <60% |
AF, atrial fibrillation CV, cardiovascular; DHF, diastolic heart failure; HF, heart failure; HFH, heart failure hospitalization; LAE, left atrial enlargement; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; NP, natriuretic peptide; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association.